XILIO THERAPEUTICS, INC.(XLO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

XLO XILIO THERAPEUTICS, INC.

盘后交易 04-15 16:46:45 EDT

8.40

-0.19

-2.21%

盘后8.05

-0.35-4.17%

16:37 EDT

最高8.74	最低8.33	成交量3.61万
今开8.57	昨收8.59	日振幅4.77%
总市值4,857万	流通市值2,659万	总股本578.25万
成交额30.93万	换手率1.14%	流通股本316.57万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"XLO","market":"US","secType":"STK","nameCN":"XILIO THERAPEUTICS, INC.","latestPrice":8.4,"timestamp":1776283200000,"preClose":8.59,"halted":0,"volume":36060,"hourTrading":{"tag":"盘后","latestPrice":8.05,"preClose":8.4,"latestTime":"16:37 EDT","volume":6,"amount":49.69999800000001,"timestamp":1776285448004,"change":-0.35,"changeRate":-0.041667,"amplitude":0.041667},"delay":0,"changeRate":-0.02211874272409773,"floatShares":3165700,"shares":5782511,"eps":-4.19,"marketStatus":"盘后交易","change":-0.19,"latestTime":"04-15 16:46:45 EDT","open":8.57,"high":8.74,"low":8.33,"amount":309265.7052,"amplitude":0.04773,"askPrice":9.75,"askSize":100,"bidPrice":7.95,"bidSize":2,"shortable":3,"etf":0,"ttmEps":-4.19,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1776297600000},"marketStatusCode":4,"adr":0,"listingDate":1634875200000,"exchange":"NASDAQ","adjPreClose":8.59,"postHourTrading":{"tag":"盘后","latestPrice":8.05,"preClose":8.4,"latestTime":"16:37 EDT","volume":6,"amount":49.69999800000001,"timestamp":1776285448004,"change":-0.35,"changeRate":-0.041667,"amplitude":0.041667},"volumeRatio":1.380826},"requestUrl":"/m/hq/s/XLO","defaultTab":"news","newsList":[{"id":"1119119277","title":"Leerink Partners因1股合14股的反向拆股将Xilio Therapeutics目标价从2美元调整为20美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1119119277","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119119277?lang=zh_cn&edition=full","pubTime":"2026-03-24 20:29","pubTimestamp":1774355355,"startTime":"0","endTime":"0","summary":"投资银行Leerink Partners宣布，因XILIO THERAPEUTICS, INC.实施1股合14股的反向拆股，已将其目标股价从原先的2美元上调至20美元。此次调整旨在反映拆股后公司股本结构的变化。\n反向拆股通常由股价较低的企业采用，旨在提升每股交易价格。尽管目标价数字表面出现大幅上调，但实际估值水平并未发生实质性改变。分析师指出，这类技术性调整需结合公司基本面及研发进展进行综合评估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XLO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111779367","title":"Xilio Therapeutics宣布根据纳斯达克上市规则5635(c)(4)授予新员工股权激励","url":"https://stock-news.laohu8.com/highlight/detail?id=1111779367","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111779367?lang=zh_cn&edition=full","pubTime":"2026-03-02 20:30","pubTimestamp":1772454651,"startTime":"0","endTime":"0","summary":"马萨诸塞州沃尔瑟姆，2026年3月2日——临床阶段生物技术公司Xilio Therapeutics, Inc.今日宣布，公司于2026年3月1日依据《2022年员工入职股票激励计划》，向两名新入职员工授予了可购买50,050股普通股的非合格股票期权。此次授予的股票期权行权价为每股0.5283美元，与公司普通股在2026年2月27日的收盘价持平。本次授予符合纳斯达克上市规则5635条款，旨在作为吸引人才加入公司的重要激励措施。Xilio Therapeutics是一家致力于开发掩蔽型免疫肿瘤疗法的临床阶段生物技术公司。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","NQmain","XLO","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162973781","title":"Xilio Therapeutics第三季度净收入为-1628.7万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1162973781","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162973781?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:40","pubTimestamp":1763574028,"startTime":"0","endTime":"0","summary":"11月13日 - Xilio Therapeutics第三季度营业收入为-192.9万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158166179","title":"Xilio Therapeutics 发布关于Vilastobart的晚期第二阶段数据，适用于MSS mCRC及高血浆肿瘤突变负担患者，在免疫治疗癌症学会(SITC)40周年年会上公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1158166179","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158166179?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:08","pubTimestamp":1763572105,"startTime":"0","endTime":"0","summary":"11月7日（路透社） - Xilio Therapeutics Inc：*XILIO THERAPEUTICS 发布关于Vilastobart的晚期第二阶段数据，适用于MSS mCRC及高血浆肿瘤突变负担患者，在免疫治疗癌症学会（SITC）第40届年会上公布。这些信息源自于发表于2025年11月7日14:05:00.14 GMT的路透社投资者简报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XLO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122495686","title":"Xilio Therapeutics发布Vilastobart在MSS MCRC及高血浆肿瘤突变负荷患者中的最新第二阶段数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1122495686","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122495686?lang=zh_cn&edition=full","pubTime":"2025-11-07 22:06","pubTimestamp":1762524375,"startTime":"0","endTime":"0","summary":"Xilio Therapeutics发布Vilastobart在MSS MCRC及高血浆肿瘤突变负荷患者中的最新第二阶段数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XLO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115293544","title":"Xilio Therapeutics宣布将在癌症免疫治疗学会(SITC)第40届年会上进行演讲展示","url":"https://stock-news.laohu8.com/highlight/detail?id=1115293544","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115293544?lang=zh_cn&edition=full","pubTime":"2025-10-03 21:01","pubTimestamp":1759496475,"startTime":"0","endTime":"0","summary":"Xilio Therapeutics宣布将在癌症免疫治疗学会(SITC)第40届年会上进行演讲展示","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156903261","title":"Xilio Therapeutics普通股转移至纳斯达克资本市场，10月6日生效","url":"https://stock-news.laohu8.com/highlight/detail?id=1156903261","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156903261?lang=zh_cn&edition=full","pubTime":"2025-10-03 19:35","pubTimestamp":1759491331,"startTime":"0","endTime":"0","summary":"根据SEC文件显示，Xilio Therapeutics将其普通股上市地点转移至纳斯达克资本市场，该变更将于10月6日生效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XLO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510377483","title":"Xilio Therapeutics(XLO)盘前涨超114% 与艾伯维达成合作与许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2510377483","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510377483?lang=zh_cn&edition=full","pubTime":"2025-02-12 22:10","pubTimestamp":1739369403,"startTime":"0","endTime":"0","summary":"金吾财讯 | Xilio Therapeutics(XLO)盘前涨超114%，报1.42美元。消息面上，艾伯维公司与Xilio Therapeutics签署了一份潜在价值超过20亿的合作和许可选择协议，旨在为Xilio提供支持。两家公司将共同开发新的肿瘤激活抗体免疫疗法。Xilio将获得5200万美元的预付款，还将有资格获得额外的21亿美元，以覆盖与选择相关的费用和里程碑以及产品销售的版税。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250107/ZDg5MDljMjM3Zjg4MTM1NjQzMDIzNjY=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ZDg5MDljMjM3Zjg4MTM1NjQzMDIzNjY=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"285376","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4139","XLO"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xiliotx.com","stockEarnings":[{"period":"1week","weight":0.0106},{"period":"1month","weight":0.2028},{"period":"3month","weight":-0.0499},{"period":"6month","weight":-0.1905},{"period":"1year","weight":-0.1411},{"period":"ytd","weight":-0.0416}],"compareEarnings":[{"period":"1week","weight":0.0535},{"period":"1month","weight":0.0486},{"period":"3month","weight":0.0059},{"period":"6month","weight":0.0512},{"period":"1year","weight":0.2881},{"period":"ytd","weight":0.0184}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Xilio Therapeutics, Inc.于2020年6月18日在特拉华州注册成立。该公司是一家临床阶段的生物技术公司，发现并开发掩蔽免疫生态学（I-O）疗法，旨在显著改善癌症患者的预后。利用其临床验证的掩蔽技术和能力，该公司正在开发I-O疗法，旨在在肿瘤微环境中选择性激活，以实现持久疗效，而不会产生与系统活性I-O药物相关的严重副作用。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.011356},{"month":2,"riseRate":0.4,"avgChangeRate":0.023701},{"month":3,"riseRate":0.4,"avgChangeRate":-0.012363},{"month":4,"riseRate":0.6,"avgChangeRate":-0.083664},{"month":5,"riseRate":0.5,"avgChangeRate":0.052494},{"month":6,"riseRate":0,"avgChangeRate":-0.163729},{"month":7,"riseRate":0.5,"avgChangeRate":0.01036},{"month":8,"riseRate":0.5,"avgChangeRate":-0.060444},{"month":9,"riseRate":0.5,"avgChangeRate":0.039039},{"month":10,"riseRate":0.5,"avgChangeRate":0.099935},{"month":11,"riseRate":0.2,"avgChangeRate":-0.160439},{"month":12,"riseRate":0.4,"avgChangeRate":-0.10922}],"exchange":"NASDAQ","name":"XILIO THERAPEUTICS, INC.","nameEN":"XILIO THERAPEUTICS, INC."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.41.0","shortVersion":"4.41.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"XILIO THERAPEUTICS, INC.(XLO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供XILIO THERAPEUTICS, INC.(XLO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"XILIO THERAPEUTICS, INC.,XLO,XILIO THERAPEUTICS, INC.股票,XILIO THERAPEUTICS, INC.股票老虎,XILIO THERAPEUTICS, INC.股票老虎国际,XILIO THERAPEUTICS, INC.行情,XILIO THERAPEUTICS, INC.股票行情,XILIO THERAPEUTICS, INC.股价,XILIO THERAPEUTICS, INC.股市,XILIO THERAPEUTICS, INC.股票价格,XILIO THERAPEUTICS, INC.股票交易,XILIO THERAPEUTICS, INC.股票购买,XILIO THERAPEUTICS, INC.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"XILIO THERAPEUTICS, INC.(XLO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供XILIO THERAPEUTICS, INC.(XLO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}